


## LEGEND-T2DM Evidence Dissemination Summary

Target: **linagliptin**, Comparator: **saxagliptin** Outcome: **Bladder cancer**

### How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	128,174	106,505	138	1.30
Merative CCAE	4,512	3,182	<5	<1.57
Merative MDCCD	-	-	-	-
Merative MDCR	1,820	1,786	<5	<2.80
Optum Clinformatics	12,319	9,897	15	1.52
Optum EHR	8,743	1,827	<5	<2.74
Veterans Affairs	-	-	-	-

### How Reliable Are the Effect Estimates? (Objective diagnostics)



### What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

